"Pipeline" patent bill
House Judiciary/Courts & Intellectual Property Subcommittee will hold a hearing July 1 on Reps. Bryant (R-Tenn.) and McDermott's (D-Wash.) Patent Fairness Act (HR 1598). The bill would extend patent exclusivity for "pipeline" drugs that were in development when the 1984 Waxman/Hatch patent legislation passed and which subsequently experienced delays in FDA approval. The subcommittee cancelled a previously scheduled hearing on the issue ("The Pink Sheet" April 26, p. 36). Schering Plough's Claritin (loratadine) and SmithKline Beecham's Relafen (nabumetone) are among products that would potentially benefit from the bill
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth